114 related articles for article (PubMed ID: 21934681)
1. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
[TBL] [Abstract][Full Text] [Related]
2. YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models.
Böckelmann LC; Felix T; Calabrò S; Schumacher U
Cell Oncol (Dordr); 2021 Oct; 44(5):1183-1195. PubMed ID: 34432260
[TBL] [Abstract][Full Text] [Related]
3. Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.
Kazakova M; Ivanova T; Dikov D; Molander D; Simitchiev K; Sbirkov Y; Dzhambov AM; Sarafian V
Heliyon; 2024 Mar; 10(5):e27570. PubMed ID: 38495157
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
[TBL] [Abstract][Full Text] [Related]
5. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients.
Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F
Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271
[TBL] [Abstract][Full Text] [Related]
6. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.
Volck B; Price PA; Johansen JS; Sørensen O; Benfield TL; Nielsen HJ; Calafat J; Borregaard N
Proc Assoc Am Physicians; 1998; 110(4):351-60. PubMed ID: 9686683
[TBL] [Abstract][Full Text] [Related]
7. The role of YKL-40 in a cancerous process.
Rusak A; Jabłońska K; Dzięgiel P
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1286-1299. PubMed ID: 28026831
[TBL] [Abstract][Full Text] [Related]
8. Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder.
Wang B; Chen K; Gao M; Sun X; He W; Chen J; Yang W; Yang T; Qin H; Ruan H; Huang H; Lin T; Huang J
Clin Transl Immunology; 2024; 13(4):e1505. PubMed ID: 38623539
[TBL] [Abstract][Full Text] [Related]
9. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract][Full Text] [Related]
10. Induction of ER stress-mediated apoptosis through SOD1 upregulation by deficiency of CHI3L1 inhibits lung metastasis.
Yu JE; Yeo IJ; Yoo SS; Kim SH; Son DJ; Yun J; Han SB; Hong JT
Theranostics; 2023; 13(8):2693-2709. PubMed ID: 37215572
[TBL] [Abstract][Full Text] [Related]
11. Chitotriosidase and Neopterin as Two Novel Potential Biomarkers for Advanced Stage and Survival Prediction in Gastric Cancer-A Pilot Study.
Nechita VI; Hajjar NA; Drugan C; Cătană CS; Moiş E; Nechita MA; Graur F
Diagnostics (Basel); 2023 Apr; 13(7):. PubMed ID: 37046579
[TBL] [Abstract][Full Text] [Related]
12. CHI3L1 enhances melanoma lung metastasis
Ma B; Kamle S; Akosman B; Khan H; Lee CM; Lee CG; Elias JA
Front Immunol; 2022; 13():1056397. PubMed ID: 36618349
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer.
De Robertis M; Greco MR; Cardone RA; Mazza T; Marzano F; Mehterov N; Kazakova M; Belev N; Tullo A; Pesole G; Sarafian V; Signori E
Cells; 2022 Nov; 11(22):. PubMed ID: 36428997
[TBL] [Abstract][Full Text] [Related]
14. Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis.
Crump LS; Kines KT; Richer JK; Lyons TR
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1475-C1495. PubMed ID: 36189970
[TBL] [Abstract][Full Text] [Related]
15. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways.
Williams MM; Hafeez SA; Christenson JL; O'Neill KI; Hammond NG; Richer JK
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832904
[TBL] [Abstract][Full Text] [Related]
16. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
Ma B; Akosman B; Kamle S; Lee CM; He CH; Koo JS; Lee CG; Elias JA
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720089
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer.
Oh IH; Pyo JS; Son BK
Curr Oncol; 2021 Aug; 28(4):3139-3149. PubMed ID: 34436040
[TBL] [Abstract][Full Text] [Related]
18. Chitinase-3 like-protein-1 function and its role in diseases.
Zhao T; Su Z; Li Y; Zhang X; You Q
Signal Transduct Target Ther; 2020 Sep; 5(1):201. PubMed ID: 32929074
[TBL] [Abstract][Full Text] [Related]
19. Assessment of YKL-40, lipid profile, antioxidant status, and some trace elements in benign and malignant breast proliferation.
Shahy EM; Taha MM; Ibrahim KS
Mol Biol Rep; 2020 Sep; 47(9):6973-6982. PubMed ID: 32876843
[TBL] [Abstract][Full Text] [Related]
20. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer.
Kzhyshkowska J; Larionova I; Liu T
Front Immunol; 2019; 10():2930. PubMed ID: 32038607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
